目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T63264 | |||
EGFR-IN-33 是一种丙烯酰胺衍生物,是低毒副作用的抗肿瘤药物,是 EGFR 的有效抑制剂。其中表皮生长因子受体 (EGFR) 的过度表达和突变已被证实会导致细胞无节制的生长,并与大多数癌症疾病,尤其是 NSCLC 的进展有关。EGFR-IN-33 表现出 EGFR 突变相关疾病的研究潜力。 | |||
T63283 | |||
EGFR-IN-38 是一种低毒副作用的、丙烯酰胺衍生物的抗肿瘤药物,是 EGFR 的有效抑制剂。其中表皮生长因子受体 (EGFR) 的过度表达和突变已被证实会导致细胞无节制的生长,并与大多数癌症疾病,尤其是 NSCLC 的进展有关。EGFR-IN-38 表现出 EGFR 突变相关疾病的研究潜力。 | |||
T74438 | |||
β-Glucuronide-dPBD-PEG5-NH2 TFA 是一种通过β-葡糖苷酸与pyrrolobenzodiazepine形成的二聚体,能够与异戊二烯化的抗体结合,生成抗体-活性分子偶联物(ADC) cIRCR201-dPBD。该化合物中的β-葡糖苷酸键作为可降解的ADC Linker,有助于减少副作用。β-Glucuronide-dPBD-PEG5-NH2 TFA 作为cIRCR201-dPBD的前体,显示出能诱导细胞凋亡(apoptosis)和阻滞细胞周期,具备抗肿瘤活性。 | |||
T10177 | Apoptosis | ||
(5Z,2E)-CU-3 是一种具有有效性和选择性的 DGKα 同工酶抑制剂,IC50 值为 0.6 μM,通过对竞争ATP来抑制 DGKα,Km 值为 0.48 mM。(5Z,2E)-CU-3 具有选择性,靶向 DGKα 催化区域,但不作用于调节区域。(5Z,2E)-CU-3 具有抗肿瘤和免疫原性作用,促进癌细胞的凋亡和 T 细胞的活化。 | |||
T81596 | EGFR | ||
Os30是一款针对EGFRC797S-TK活性的第四代EGFR抑制剂,其针对EGFRDel19/T790M/C797S TK和EGFRL858R/T790M/C797S TK的IC50值为18 nM与113 nM。该化合物能够抑制EGFR磷酸化作用,导致KC-0116细胞在G1期停滞,并促使KC-0116(BaF3-EGFRDel19/T790M/C797S)细胞发生凋亡。对携带EGFmRC797S突变的非小细胞肺癌(NSCLC)显示有显著的抗癌效果。 | |||
T76378 | |||
RGD-4C(ACDCRGDCFC)是一种携带Arg-Gly-Asp(RGD)序列的肽,具备与αv整合素结合的能力,用于模拟细胞外基质蛋白的整合素识别特性。作为αv整合素的配体,它能够与生物活性分子进行偶联,进而在动物模型中展现出抗肿瘤活性。 | |||
T77908 | |||
Farletuzumabecteribulin(MORAb-202)是一款人源化抗人叶酸受体α(FRA)抗体Farletuzumab与Mal-PEG2-Val-Cit-PAB-eribulin通过还原的链间二硫键偶联成的抗体-活性分子偶联物(ADC)。该化合物活性分子抗体比率为4.0,对FRA阳性细胞展示出强大的体外细胞毒性,并具备有效的抗肿瘤活性。 | |||
T62681 | |||
PDE5-IN-3 (compound 11j) 是一种 PDE5 的有效抑制剂 (IC50: 1.57 nM)。PDE5-IN-3 对 EGFR 具有中度抑制作用 (IC50: 5.827 μM)。PDE5-IN-3 明显抑制 Wnt/β-catenin 通路,其 IC50 值为 1286.96 ng/mL。PDE5-IN-3 在 HepG2 细胞中诱导内在的凋亡线粒体途径。PDE5-IN-3 表现出显著的抗肿瘤效果。 | |||
T60933 | |||
B-Raf IN 7 (compound 6a) 是 B-Raf 的有效抑制剂,IC50值为 110.23 nM。B-Raf IN 7 对结肠癌细胞(HCT-116)、乳腺癌细胞 (MCF-7)、肝癌细胞 (HEPG-2)、人宫颈癌细胞 (Hela) 和人前列腺癌细胞 (PC-3) 具有抗肿瘤活性。其 IC50值分别为 7.50、9.87、10.57、11.63 和 12.83 μM。 | |||
T81169 | |||
Shishijimicin B为活性的烯二炔类化合物,具有强烈的细胞毒性,IC50值介于2.0 - 3.3 nM。此化合物表现出抗肿瘤活性,常用于癌症研究中。作为点击化学试剂,Shishijimicin B内含Alkyne基团,能通过含Azide基团的分子在铜催化下发生(CuAAc)反应。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-06983 | IFN gamma Protein, Human, Recombinant (E. coli) | Human | E. coli | ||
IFN gamma, also known as IFNG, is a secreted protein that belongs to the type II interferon family. IFN gamma is produced predominantly by natural killer and natural killer T cells as part of the innate immune response, and by CD4 and CD8 cytotoxic T lymphocyte effector T cells once antigen-specific immunity develops. IFN gamma has antiviral, immunoregulatory, and anti-tumor properties. IFNG, in addition to having antiviral activity, has important immunoregulatory functions, it is a potent activator of macrophages and has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. The IFNG monomer consists of a core of six α-helices and an extended unfolded sequence in the C-terminal region. IFN gamma is critical for innate and adaptive immunity against viral and intracellular bacterial infections and tumor control. Aberrant IFN gamma expression is associated with some autoinflammatory and autoimmune diseases. The importance of IFN gamma in the immune system stems in part from its ability to inhibit viral replication directly, and most importantly from its immunostimulatory and immunomodulatory effects. IFNG also promotes NK cell activity.
|
|||||
TMPH-03055 | Ribonuclease mitogillin Protein, Neosartorya fumigata, Recombinant (His & Myc & SUMO) | Neosartorya fumigata | E. coli | ||
This purine-specific ribonuclease cleaves 28S RNA in eukaryotic ribosomes, inhibits protein synthesis, and shows antitumor activity.
|
|||||
TMPK-01520 | HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01417 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01519 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPH-00131 | Ribonuclease mitogillin Protein, Aspergillus restrictus, Recombinant (His & Myc) | Aspergillus restrictus | E. coli | ||
This purine-specific ribonuclease cleaves 28S RNA in eukaryotic ribosomes, inhibits protein synthesis, and shows antitumor activity. Ribonuclease mitogillin Protein, Aspergillus restrictus, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 23.9 kDa and the accession number is P67876.
|
|||||
TMPK-01478 | HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01436 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01521 | HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01477 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPJ-00008 | CXCL10 Protein, Human, Recombinant (hFc & His) | Human | HEK293 Cells | ||
Human C-X-C Motif Chemokine Ligand 10 (CXCL10) is a non-ELR chemokine secreted by various cell types, such as monocytes, endothelial cells and fibroblasts, in response to IFN-γ. CXCL10 functions via chemokine receptor CXCR3. CXCL10 has been attributed to several roles, such as chemoattraction for activated T-lymphocytes, inhibition of angiogenesis, and antitumor activity.
|
|||||
TMPK-01484 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPH-00373 | IFN gamma Protein, Chicken, Recombinant (GST) | Chicken | E. coli | ||
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. IFN gamma Protein, Chicken, Recombinant (GST) is expressed in E. coli expression system with N-GST tag. The predicted molecular weight is 43.7 kDa and the accession number is P49708.
|
|||||
TMPK-01482 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-00126 | CLEC4A Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy. CLEC4A Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-hFc tag. The predicted molecular weight is 46.7 kDa and the accession number is Q9UMR7-1.
|
|||||
TMPK-00127 | CLEC4A Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy. CLEC4A Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-hFc tag. The predicted molecular weight is 46.3 kDa and the accession number is Q9QZ15.
|
|||||
TMPK-01483 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01515 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-00248 | TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages. TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 19.4 kDa and the accession number is Q9UBN6.
|
|||||
TMPH-02451 | IFN gamma Protein, Marmota monax, Recombinant (His) | Marmota monax | P. pastoris (Yeast) | ||
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. IFN gamma Protein, Marmota monax, Recombinant (His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 18.6 kDa and the accession number is O35735.
|
|||||
TMPK-00249 | TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages. TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 19.4 kDa and the accession number is Q9UBN6.
|
|||||
TMPJ-00076 | IL-28B Protein, Human, Recombinant | Human | HEK293 Cells | ||
Interleukin-28B, also known as Cytokine Zcyto22, Interferon lambda-3, Interferon lambda-4, IFNL3, IFNL4, ZCYTO22 and IL28B, is a secreted cytokine which belongs to the IL-28/IL-29 family. IL-28 has also been shown to play a role in the adaptive immune response. IL28B has immunomodulatory activity and up-regulates MHC class I antigen expression. IL28B displays potent antiviral activity and antitumor activity. In addition, IL28B is a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IL28RA. The ligand/receptor complex seems to signal through the Jak-STAT pathway.
|
|||||
TMPH-00775 | IFN gamma Protein, Goat, Recombinant (His & Myc) | Goat | E. coli | ||
Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription. Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits. In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading. Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference. Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL. Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation.
|
|||||
TMPH-02524 | Arginase-1/ARG1 Protein, Mouse, Recombinant (His) | Mouse | P. pastoris (Yeast) | ||
Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively; the urea cycle takes place primarily in the liver and, to a lesser extent, in the kidneys.; Functions in L-arginine homeostasis in nonhepatic tissues characterized by the competition between nitric oxide synthase (NOS) and arginase for the available intracellular substrate arginine. Arginine metabolism is a critical regulator of innate and adaptive immune responses. Involved in an antimicrobial effector pathway in polymorphonuclear granulocytes (PMN). Upon PMN cell death is liberated from the phagolysosome and depletes arginine in the microenvironment leading to suppressed T cell and natural killer (NK) cell proliferation and cytokine secretion. In group 2 innate lymphoid cells (ILC2s) promotes acute type 2 inflammation in the lung and is involved in optimal ILC2 proliferation but not survival. Plays a role in the immune response of alternatively activated or M2 macrophages in processes such as wound healing and tissue regeneration, immune defense against multicellular pathogens and parasites, and immune suppression and allergic inflammation; the regulatory outcome seems to be organ specific. In tumor-infiltrating dendritic cells (DCs) and myeloid-derived suppressor cells (MDSCs) plays a role in suppression of T cell-mediated antitumor immunity.
|